| Literature DB >> 32641214 |
Ismael Henarejos-Castillo1, Patricia Sebastian-Leon2, Almudena Devesa-Peiro1, Antonio Pellicer1, Patricia Diaz-Gimeno3.
Abstract
OBJECTIVE: To determine the susceptibility of the endometrium to infection by-and thereby potential damage from-SARS-CoV-2.Entities:
Keywords: ACE2; COVID-19; SARS-CoV-2; coronavirus; endometrial transcriptomics
Mesh:
Substances:
Year: 2020 PMID: 32641214 PMCID: PMC7298504 DOI: 10.1016/j.fertnstert.2020.06.026
Source DB: PubMed Journal: Fertil Steril ISSN: 0015-0282 Impact factor: 7.490
Characterization of endometrial transcriptomic data sets with GEO data sets identifier, experiment name given for this study, cycle type, method of cycle phase dating, population from which samples were collected, age, transcriptomic platform used to measure gene expression, number of genes of each data set, number of samples in each data set, number of samples per cycle phase, and publication in which data were initially employed.
| GEO ID | Experiment name | Cycle type | Cycle phase dating method | Population | Age | Platform | No. genes | No. samples | No. samples per cycle phase | Reference |
|---|---|---|---|---|---|---|---|---|---|---|
| Talbi 2006 | Normo-ovulatory; regular (24–35 d); 3 mo since last hormone treatment | Noyes et al. ( | Caucasian (n = 17); black (n = 6); Asian (n = 1); other (n = 2) | 23–50 | hgu133plus2 Affymetrix | 19,361 | 27 | PF (n = 6); ESE (n = 4); MSE (n = 9); LSE (n = 8) | ( | |
| Bradley 2010 | Regular | Days from LH peak: PF (LH-14–LH-1), ESE (LH+1–LH+4), MSE (LH+6–LH+7) | Collected in Belgium | 20–39 | hgu133plus2 Affymetrix | 19,361 | 19 | PF (n = 10); ESE (n = 6); MSE (n = 3) | — | |
| Altmäe 2017 | Natural cycle | Days from LH peak. We classified it in ESE = LH+2; MSE = LH+8 | Collected in Estonia | — | Illumina HiSeq 2500 | 16,426 | 38 | ESE (n = 19); MSE (n = 19) | ( | |
| Sigurgeirsson 2017 | Regular; 3 mo since last hormone treatment | Urinary LH ovulation predictor kit for MSE-LSE, days after the start of the subsequent menstruation for PF. Both confirmed by a gynecologic pathologist through histopathologic examination. | Collected in Iceland | 24–30 | Illumina HiSeq 2500 | 15,939 | 14 | PF (n = 7); MSE (n = 7) | ( | |
| Kelleher 2017 | — | — | Collected in U.S. | — | Illumina HiSeq 2500 | 17,934 | 11 | PF (n = 6); MSE (n = 5) | — |
Note: Last row indicates the total number of samples accounted and genes in common between all data sets for all menstrual cycle phases (53, 54, 55). ESE = early secretory; GEO = Gene Expression Omnibus; LH = luteinizing hormone; LSE = late secretory; MSE = medium secretory; PF = proliferative phase.
Figure 1Endometrial data set integration and menstrual cycle clock. (A) Data set experiment effect and correction. Each point of the principal component analysis (PCA) plots represents endometrial gene expression of one sample and is colored by the endometrial transcriptomic data sets to which it belongs. Principal component 1 (PC1) and principal component 2 (PC2) explain the percentage of variability due to these components for each PCA. Integration of the transcriptomic studies showed a clear batch effect by the nature of each experiment (left PCA plot). After correction (right PCA plot), all genes in common between data sets were retained, amounting to a total of 13,437 genes, as no differentially expressed genes were detected between experiments. (B) Menstrual cycle effect. The samples of the integrated data sets are colored by the menstrual cycle phase to show how they are grouped by phases of the menstrual cycle. ESE = early secretory endometrium; LSE = late secretory endometrium; MSE = midsecretory endometrium; PF = proliferative phase.
Figure 2Gene expression of viral infection-related genes throughout the menstrual cycle. (A) Landscape of expression changes. Genes were located depending on their relative expression against the whole set. Low, medium, and high expression thresholds correspond to 1% to 10%, 11% to 50%, and 51% to 100% categories of gene expression values of the entire integrated data set, respectively. Analysis of variance results for overall change of expression during cycle are shown for each gene. ∗P<.05; ∗∗∗P<.0001. (B) Molecular scheme of SARS-CoV-2 endometrial infection. ACE2, TMPRSS4, FURIN, and BSG are shown in plasma membrane of an endometrial cell (lower left figure). CTSL and CTSB are represented outside the cell. MX1 is shown in cytoplasm. Expression of viral genes in comparison to whole transcriptomic set is represented as arrows next to their names: up = highly expressed; down = lowly expressed. Viral genes are positioned in their schematized cell locations as stablished by GeneCards database > Localization section (release 4.14) (56). Only maximum confidence levels (5 and 4) for compartments-derived cell locations were used. Proteins were grouped considering the highest coactivation values between pairs of viral genes during the menstrual cycle, which are shown in the lower right table in the figure. Discontinuous arrow shows less evidence according to our results, given that only FURIN showed high activation with BSG and that further studies are needed to understand BSG-related mechanisms of SARS-CoV-2 entry. ESE = early secretory endometrium; LSE = late secretory endometrium; MSE = midsecretory endometrium; PF = proliferative phase.
Figure 3Impact of age on viral-related infectivity gene expression throughout the menstrual cycle. (A) Effect of age on ACE2 expression. Gene expression is represented for ACE2 in each phase of the cycle according to the age of the sample analyzed. The range of age from patients involved in this study was 23 to 50 years. (B) Effect of age on viral gene expression. Pearson correlation R2 values are shown for each gene studied through of the phases of the menstrual cycle. Gray scale represents the magnitude of the correlation of increase or decrease in expression with age. High values are colored darker, and low values are colored lighter. ESE = early secretory endometrium; LSE = late secretory endometrium; MSE = midsecretory endometrium; PF = proliferative phase.